Ag biologicals market: four possible futures over the next decade
Industry specialist Gustavo Mamao uses scenario planning to outline four possible paths for the agricultural biologicals market over 10 years. They depend on how well new technologies perform and how readily they fit existing manufacturing and distribution systems.
Gustavo Mamao, who co-founded an agricultural biocontrol company later acquired by Stoller and advises Brazilian biologicals contract manufacturer IdeeLab, has published a guest article on AgFunderNews. Using scenario planning, he examines how the market for agricultural biological inputs (products such as biocontrol agents and other living or nature-derived crop treatments) could evolve over the next decade. The piece reflects the author's own views.
Where the market stands
According to DunhamTrimmer, the sector continues to grow at double-digit rates, and in some crops and regions biologicals are becoming mainstream. However, they are less stable than synthetic chemicals, so activity present at the factory can be lost before application in the field. Field results may fall short of promises, while the most commoditized products face falling prices because tens or even hundreds of companies can make them.
Newer technologies include metabolites, proteins and peptides, genetically modified microorganisms and RNAi-based solutions.
Two key uncertainties
The author picked two high-impact, uncertain drivers: how well the new platforms actually perform, and how well agricultural-input companies can integrate them into portfolios and distribution channels. Combining them yields four scenarios:
- Biologicals at scale – strong performance gains and high system fit; differentiated technologies enter mainstream portfolios.
- New system required – the technology works but does not fit existing manufacturing and distribution; two markets emerge, and bridge builders and specialized manufacturers gain ground.
- Integrated but incremental – modest improvements that the system can absorb; competition shifts to price, brand and distribution, favoring portfolio players.
- Fragmented process – promises outpace results and scaling is costly; niches tied to particular crops and regions survive.
Advice for companies
For established input companies, the author stresses integration and grower education. Specialized biological firms with more than $20 million in revenue need to lead on innovation to avoid the commoditization trap. Startups, operating with scarcer capital, may benefit from working with incumbent systems or specialized manufacturers. He urges companies to run their own scenario exercises and watch for early signals of which future is unfolding.
